IP Library › Granted Patent US 12,702,677
Granted Patent B2
US 12,702,677 · App. 18/489,630 · Granted Aug 11, 2026

Antiviral supplement formulations

Inventors: Kenneth E. Phillips (Tulsa, OK); Cynthia A. Winning (Parker, CO)
Assignee: Vymedic, LLC
A61K31/7028A61K31/145A61K31/185A61K31/198A61K31/221A61K31/375A61K31/44A61K31/4415A61K31/455A61K31/513A61K31/7048A61K45/06Y02A50/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,702,677
App. No.
18/489,630
Granted
Aug 11, 2026
Kind
B2
Abstract

The disclosure provides an oral antiviral supplement composition comprising a lysine, an ascorbic compound, a flavonoid glycoside, a threonine, and a pyridoxine. The disclosure also provides a method of reducing viral replication in a cell comprising treating a virus-infected cell with a composition of the disclosure. The disclosure further provides a method for the treatment and prophylaxis of a viral infection in a patient comprising administering a composition of the disclosure.

Claims (24)

1 . A method of making an antiviral supplement tablet comprising mixing active ingredients including:

from about 40% to about 80% by weight of a L-lysine hydrochloride;

from about 15% to about 35% by combined weight of one or more ascorbic compounds;

from about 5% to about 20% by weight of one or more flavonoid glycosides, wherein the one or more flavonoid glycosides comprise hesperidin and rutin;

from about 0.1% to about 5% by weight of L-threonine;

from about 1% to about 10% by weight of a taurine; and

from about 0.1% to about 2% by weight of pyridoxine hydrochloride, compared to total weight of the active ingredients, with a pharmaceutically acceptable carrier to form a composition; and

forming a tablet from the composition.

2 . The method of claim 1 , wherein the forming comprises a process selected from the group consisting of wet granulation, dry granulation, and direct compression.

3 . The method of claim 1 , wherein the tablet is selected from the group consisting of orally disintegrable tablet, swallowable tablet, coated tablet, effervescent tablet, and chewable tablet.

4 . The method of claim 1 , wherein the L-lysine hydrochloride is from about 50% to about 70% by weight, compared to the total weight of the active ingredients.

5 . The method of claim 1 , wherein the L-lysine hydrochloride is selected from the group consisting of L-lysine monohydrochloride, and L-lysine dihydrochloride.

6 . The method of claim 1 , wherein combined weight of the one or more ascorbic compounds is from about 20% to about 30% by weight, compared to the total weight of the active ingredients.

7 . The method of claim 1 , wherein the one or more ascorbic compounds are selected from the group consisting of ascorbic acid, calcium ascorbate, magnesium ascorbate, potassium ascorbate, sodium ascorbate, manganese ascorbate, zinc ascorbate, iron ascorbate, copper ascorbate, boron ascorbate, molybdenum ascorbate, chromium ascorbate, ascorbyl palmitate, ascorbyl arachidonate, ascorbyl stearate, ascorbyllinoleate, ascorbyl linoleneate, and ascorbyl oleate.

8 . The method of claim 1 , wherein combined weight of the one or more flavonoid glycosides is from about 10% to about 15% by weight compared to the total weight of the active ingredients.

9 . The method of claim 1 , wherein the flavonoid glycoside comprises hesperidin and rutin in a 1:1 weight ratio.

10 . The method of claim 1 , wherein the L-threonine is from about 0.5% to about 2% by weight compared to the total weight of the active ingredients.

11 . The method of claim 1 , wherein the taurine is from about 2% to about 6% by weight compared to the total weight of the active ingredients.

12 . The method of claim 1 , wherein the pyridoxine hydrochloride is from about 0.5% to about 1.5% by weight compared to the total weight of the active ingredients.

13 . The method of claim 1 , wherein the composition includes L-lysine monohydrochloride, ascorbic acid, hesperidin, rutin, threonine, taurine, and pyridoxine hydrochloride, and optionally an additional ascorbic compound.

14 . The method of claim 13 , wherein the additional ascorbic compound is selected from the group consisting of calcium ascorbate, niacinamide ascorbate, and ascorbyl palmitate.

15 . The method of claim 1 , wherein a single dose of the antiviral supplement comprises one or more of the tablets comprising the L-lysine hydrochloride in a combined therapeutically effective amount of from about 1,000 mg to about 5,000 mg.

16 . The method of claim 15 , wherein the single dose includes from about 2 g to about 3.5 g L-lysine monohydrochloride; from about 0.1 g to about 1.5 g ascorbic acid; from about 0.2 g to about 0.8 g hesperidin; from about 0.1 g to about 0.5 g rutin; from about 0.04 g to about 0.08 g pyridoxine hydrochloride; from about 0.01 g to about 0.08 g threonine; and from about 0.02 g to about 0.4 g taurine.

17 . The method of claim 1 , wherein the composition does not include arginine.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 27, 2023
From: PHILLIPS, KENNETH E.; WINNING, CYNTHIA A.
To: VYMEDIC, LLC
Reel/Frame 065370/0919 →
CHANGE OF NAME Recorded Oct 27, 2023
From: VYMEDIC, LLC
To: VYMEDIC INC.
Reel/Frame 065476/0736 →
Continuity (7)
Continuation 17528840 · Nov 17, 2021
Continuation 16582657 · Sep 25, 2019
Continuation 15882832 · Jan 29, 2018
Division 14681817 · Apr 8, 2015
Continuation 12609120 · Oct 30, 2009
Provisional Application 61111234 · Nov 4, 2008
Related Publication 20240075048A1 · Mar 7, 2024
References Cited (92)
US 4424232A · Parkinson · 1984 [cited by applicant]
US 5278189A · Rath et al. · 1994 [cited by applicant]
US 5626883A · Paul · 1997 [cited by applicant]
US 5650418A · Rath et al. · 1997 [cited by applicant]
US 5719133A · Schmidl et al. · 1998 [cited by applicant]
US 6037375A · Sakamoto et al. · 2000 [cited by applicant]
US 6316008B1 · Godfrey · 2001 [cited by applicant]
US 6352712B1 · Lukaczer · 2002 [cited by examiner]
US 6362225B1 · Andreakos · 2002 [cited by applicant]
US 6455061B2 · Richardson · 2002 [cited by applicant]
US 6632445B2 · Richardson et al. · 2003 [cited by applicant]
US 6939860B2 · Netke et al. · 2005 [cited by applicant]
US 6974833B2 · Rath · 2005 [cited by applicant]
US 7041699B2 · Netke et al. · 2006 [cited by applicant]
US 7351715B2 · Richardson et al. · 2008 [cited by applicant]
US 7431942B2 · Shimizu et al. · 2008 [cited by applicant]
US 9034834B2 · Phillips · 2015 [cited by examiner]
US 9907809B2 · Phillips · 2018 [cited by examiner]
US 10478447B2 · Phillips · 2019 [cited by examiner]
US 11224606B2 · Phillips · 2022 [cited by examiner]
US 11826377B2 · Phillips · 2023 [cited by examiner]
US 20010031744A1 · Kosbab · 2001 [cited by examiner]
US 20020151599A1 · Buchholz et al. · 2002 [cited by applicant]
US 20030064104A1 · Stillman · 2003 [cited by applicant]
US 20030170319A1 · Netke et al. · 2003 [cited by applicant]
US 20040067890A1 · Gupta · 2004 [cited by applicant]
US 20040220118A1 · Bland · 2004 [cited by examiner]
US 20050032715A1 · Netke et al. · 2005 [cited by applicant]
US 20050281794A1 · Rath · 2005 [cited by applicant]
US 20060088574A1 · Manning · 2006 [cited by examiner]
US 20060142212A1 · Netke et al. · 2006 [cited by applicant]
US 20070134320A1 · Lowder · 2007 [cited by applicant]
US 20070160591A1 · Lane · 2007 [cited by examiner]
US 20070212426A1 · Rath et al. · 2007 [cited by applicant]
US 20080038367A1 · Saloum · 2008 [cited by examiner]
CN 1650911A · 2005 [cited by examiner]
EP 0799578A2 · 1997 [cited by applicant]
EP 1036510A2 · 2000 [cited by examiner]
KR 100363180B1 · 2000 [cited by examiner]
RU 2217138C1 · 2003 [cited by examiner]
RU 2217141C1 · 2003 [cited by examiner]
WO 1992015315A1 · 1992 [cited by applicant]
WO 2007057748A2 · 2007 [cited by applicant]
WO WO2007094498A1 · 2007 [cited by examiner]
WO 2007106675A2 · 2007 [cited by applicant]
ZA 200402741 · 2004 [cited by applicant]
Pinnell, Sheldon R. “Ascorbyl-6-palmitate is not ascorbic acid.” Journal of investigative dermatology 119.5 (2002): 991. (Year: 2002). [cited by examiner]
Rotelli, Alejandra Ester, et al. “Comparative study of flavonoids in experimental models of inflammation.” Pharmacological research 48.6 (2003): 601-606. (Year: 2003). [cited by examiner]
English translation of KR100363180. Received Apr. 30, 2025 from Google Patents. [cited by examiner]
English translation of RU2217141. Received Apr. 30, 2025 from Google Patents. [cited by examiner]
English translation of WO2007094498. Received Apr. 30, 2025 from Google Patents. [cited by examiner]
English translation of CN1650911. Obtained from Espacenet on Oct. 24, 2025 (Year: 2025). [cited by examiner]
English translation of RU2217138. Obtained from Espacenet on Oct. 24, 2025 (Year: 2025). [cited by examiner]
Axelrod et al., “Effects of Pantothenic Acid, Pyridoxine and Thiamine Deficiencies upon Antibody Formation to Influenza Virus PR-8 in Rats”; J. Nutrition, 72:325-330 (1980). [cited by applicant]
Barbour et al., “Alleviation of Histopathologic Effects of Avian Influenza Virus by a Specific Nutrient Synergy”; Intern. J. Appl. Res. Vet. Med., 5(1):9-16 (2007). [cited by applicant]
Barrett, “Wisconsin Upper Respiratory Symptom Survery (WURSS)”, 2017, URL: https://www.fammed.wisc.edu/wurss/, retrieved Jan. 3, 2019, 11 pages total. [cited by applicant]
Barrett et al., “The Wisconsin Upper Respiratory Symptom Survey is responsive, reliable, and valid”, Journal of Clinical Epidemiology 58 (2005) 609-617. [cited by applicant]
Barrett et al., 2006, Wisconsin Upper Respiratory Symptom Survey—WURSS-24—Daily Symptom Report, 1 page total. [cited by applicant]
Barrett et al., “Validation of a short form Wisconsin Upper Respiratory Symptom Srvey (WURSS-21)”, Health and Quality of Life Outcomes 2009, 7:76. [cited by applicant]
Becht, “Induction of an Arginine-rich Component During Infection with Influenza Virus”; J. Gen. Virol., 4:215-220 (1969). [cited by applicant]
Boon et al., “In vitro effect of bioactive compounds on influenza virus specific B- and T-cell response”, Jan. 1, 2002, URL: http://onlinelibrary.wiley.com/store/10.1046/j.1365-3083.2002.01014.x/asset/j.1365-3083.2002.0… [cited by applicant]
Braverman, “Taurine: The Seizure Fighter,” The Healing Nutrients Within, 2003, pp. 131-143. [cited by applicant]
Braverman, “Threonine: The Immunity Booster,” The Healing Nutrients Within, 2003, pp. 201-207. [cited by applicant]
Cai et al., “Inhibition of influenza infection by glutathione”, Free Rad. Biol. and Med., (2003), vol. 34, No. 7, pp. 928-936. [cited by applicant]
CDC, Updated Interim Recommendations for the Use of Antiviral Medications in the Treatment and Prevention of Influenza for the 2009-2010 Season, (Sep. 22, 2009), URL: http://www.cdc.gov/h1n1flu/recommendations.htm. [cited by applicant]
Chorazy et al., “Taurine chloramine modulates cytokine production by human peripheral blood mononuclear cells”; Amino Acids, 23:407-413 (2002). [cited by applicant]
Dharan et al., “Infections with Oseltamivir-resistant influenza A(H1N1) virus in the United States”, JAMA, (2009), vol. 301, No. 10, pp. 1034-1041. [cited by applicant]
Dubber et al., “High-performance liquid chroomatographic determination of selected flavonols in Ginkgo biloba solid oral dosage forms.”, J Phar Pharmaceut Sci, 2004, vol. 7, No. 3, pp. 303-309. [cited by applicant]
Extended European Search Report and Written Opinion mailed Apr. 23, 2012 in 09825263.8. [cited by applicant]
Friedman, “Absorption and Utilization of Amino Acids”; CRC Press, vol. II, Ch. III, pp. 48-49, ISBN 0849360072 (1989). [cited by applicant]
Fuchs et al., EP0799578 A2 Oct. 8, 1997 (Machine English Translation). [cited by applicant]
Green et al., “Antioxidant role and subcellular location of hypotaurine and taurine in human neutrophils”; Biochimica et biophysica acta, 1073(1):91-97 (Jan. 23, 1991). [cited by applicant]
Griffith et al., “Success of L-lysine Therapy in Frequently Recurrent Herpes Simplex Infection. Treatment and prophylaxis”; Dermatologica, 175(4):183-190 (1987). [cited by applicant]
Grimble, “The effects of Sulfur Amino Acid Intake on Immune Function in Humans”; 5th Amino Acid Assessment Workshop, J. Nutrition, 136:1660S-1665S (2006). [cited by applicant]
Hatakeyama et al., “Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors”, JAMA, (2007), vol. 297, No. 13, pp. 1492-1493. [cited by applicant]
Hurt et al., “Zanamivir-resistant influenza viruses with a novel neuraminidase mutation,” J. Virology, (Oct. 2009), vol. 83, No. 20, pp. 10366-10373. [cited by applicant]
Huxtable, “Taurine. Past, present, and future”; Adv Exp Med Biol. 403:641-650 (1996). [cited by applicant]
International Search Report and Written Opinion mailed Feb. 1, 2010 in PCT/US09/62673. [cited by applicant]
Kamali et al., “Influenza treatment and prophylaxis with neuraminidase inhibitors: a review”, Infection and Drug Resistance 2013:6 187-198. [cited by applicant]
Kim et al., “Flavanone Glycosides from Citrus junos and their Anti-Influenza Virus Activity”; Planta Med, 67(6):548-549 (Aug. 2001). [cited by applicant]
Lotan, “Humoral and Cellular Immune Response in Growing Rats Fed a 10% Gluten Diet”; Isr. J. Med. Sci. 25 (8):437-441 (Aug. 1989). [cited by applicant]
Molecular Probes, Amplex® Red Neuraminidase (Sialidase) Assay Kit (A22178) (Product Information Rev. Oct. 1, 2004). [cited by applicant]
Moscona, “Neuraminidase inhibitors for influenza”, N Engl J Med 2005; 353:1363-1373. [cited by applicant]
“Prevention & Control of Influenza—Recommendations of the Advisory Committee on Immunization Practices (ACIP) 2004”, MMWR, (May 28, 2004), vol. 53, No. RR06, pp. 1-40. [cited by applicant]
Riley et al., “Secretion of matrix metalloproteinase-2, matrix metalloproteinase-9 and tissue inhibitor of metalloproteinases into the intrauterine compartments during early pregnancy”, Molecul. Human Reprod, (1999), vo… [cited by applicant]
Roomi et al., “Modulation of N-methyl-N-nitrosurea induced mammary tumors in Sprague-Dawley rats by combination of lysine, praline, arginine, ascorbic acid, and green tea extract”; Breast Cancer Res., 7(3): R291-R295 (2… [cited by applicant]
Sinha et al., “Taurine protects the antioxidant defence system in the erythrocytes of cadmium treated mice”; BMB Reports, 41(9):657-663 (2008). [cited by applicant]
Tamiflu prescribing information, 2016, 27 pages total. [cited by applicant]
Trakatellis et al., “Pyridoxine deficiency: new approaches in immunosuppression and chemotherapy”; Postgrad. Med. J., 73(864):617-622 (1997). [cited by applicant]
United States Pharmacopeia National Formulary USP, (1990), vol. XXII, pp. 1696-1697. [cited by applicant]
Williams et al., “Flavonoids: Antioxidants or Signalling Molecules?”; Free Radic. Biol. Med., 36(7):838-849 (2004). [cited by applicant]
Yeo et al., “Influenza A virus infection modulates expression of type IV collgenase in epithelial cells”; Arch. Virol., 144:1361-1370 (1999). [cited by applicant]